Sp214
LIRAGLUTIDE TO TREAT BAD
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
Bile acid diarrhea is a poorly recognized cause of bowel symptoms. The pathophysiology is varied and includes bile acid overproduction and malabsorption. Recent studies have provided new evidence of targets for therapy and will be reviewed in this session.
Bile acid diarrhea is a poorly recognized cause of bowel symptoms. The pathophysiology is varied and includes bile acid overproduction and malabsorption. Recent studies have provided new evidence of targets for therapy and will be reviewed in this session.
Presenter
Tracks
Related Products
PANEL DISCUSSION
Bile acid diarrhea is a poorly recognized cause of bowel symptoms. The pathophysiology is varied and includes bile acid overproduction and malabsorption. Recent studies have provided new evidence of targets for therapy and will be reviewed in this session…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
